Alzheimer’s Blood Tests Could Help High-Risk Group Get Diagnosed Earlier

Source: Newsweek

Phase 2 APPLAUDS Trial to Test Mivelsiran in Down Syndrome-Associated Alzheimer Disease

Source: NeurologyLive

The Convergence of Down Syndrome and Alzheimer’s Disease — Scientific and Ethical Imperatives

Michael S. Rafii, M.D., Ph.D.

Source: The New England Journal of Medicine

Precision medicine for Alzheimer’s disease in Down syndrome

Sonal Sukreet, Elise K. Kim, Melissa Petersen, Fan Zhang, Sid E. O'Bryant, Michael S. Rafii, Robert A. Rissman

Source: Alzheimer's & Dementia

Decoding Alzheimer’s disease through down syndrome: insights from a genetically defined population

Jason K. Russell, Zinayida Schlachetzki, Michael S. Rafii

Source: Current Opinion in Neurology

A Comparative Effectiveness Study of Lorazepam or IVIg Versus no Treatment for Down Syndrome Regression Disorder

Jonathan D. Santoro, Saba Jafarpour, Panteha Hayati Rezvan, Mellad M. Khoshnood, Benjamin N. Vogel, Lina Nguyen, Lilia Kazerooni, Noemi A. Spinazzi, Nidhiben Anadani, Kristen S. Fisher, Robyn A. Filipink, Melanie A. Manning, Cathy Franklin, Eileen A. Quinn, Michael S. Rafii

Source: Neurology and Therapy

Michael Rafii Named #1 Down syndrome Researcher Worldwide for Sixth Consecutive Year

Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down Syndrome

Jason K. Russell, Zinayida Schlachetzki, Beau M. Ances, Michael S. Rafii for the Alzheimer’s Biomarker Consortium–Down Syndrome Study

Source: JAMA Neurology

Relationship of cholinergic basal forebrain atrophy with the time course of Alzheimer’s disease pathology and cognitive decline in adults with Down syndrome: a longitudinal cohort study

Jason K. Russell, Zinayida Schlachetzki, Alexander C. Conley, Brian D. Boyd, Paul A. Newhouse, Paul S. Aisen, Michael S. Rafii, for the Alzheimer's Biomarker Consortium on Down Syndrome Study

Source: Alzheimer's & Dementia